Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Minapharm PharmaceuticalsCAI:MIPH -1.08%49 Earnings Yield (Joel Greenblatt) % is 17.54% as of Dec. 2025, which is 16% below its 10-year median of 20.81. GuruFocus rates CAI:MIPH with a GF Score™ of 49/100 and a GF Value™ of E£370.02 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Minapharm Pharmaceuticals ranks better than 78.37% on this metric.
Minapharm Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 was E£5,491 Mil.
Minapharm Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was E£963 Mil. Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) for the quarter that ended in Dec. 2025 was 17.54%.
The historical rank and industry rank for Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
CAI:MIPH'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 4.37 Med: 20.81 Max: 41.86
Current: 9.42
During the past 5 years, the highest Earnings Yield (Joel Greenblatt) of Minapharm Pharmaceuticals was 41.86%. The lowest was 4.37%. And the median was 20.81%.
CAI:MIPH's Earnings Yield (Joel Greenblatt) % is ranked better than 78.37% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.17
vs CAI:MIPH: 9.42
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Minapharm Pharmaceuticals's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2025 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Minapharm Pharmaceuticals Earnings Yield (Joel Greenblatt) % Related Terms
Minapharm Pharmaceuticals Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Minapharm Pharmaceuticals Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Minapharm Pharmaceuticals's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Minapharm Pharmaceuticalss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Minapharm Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was E£963 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 17.54% mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Earnings Yield (Joel Greenblatt) % of 17.54% as of Dec. 2025. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Minapharm Pharmaceuticals and its competitors. This is 16% below median its historical median of 20.81. Over the past decade, Minapharm Pharmaceuticals' Earnings Yield (Joel Greenblatt) % has ranged from 4.37 to 41.86. According to the industry distribution chart, Minapharm Pharmaceuticals ranks #218 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 21.6%.
Is Minapharm Pharmaceuticals' Earnings Yield (Joel Greenblatt) % too high?
Minapharm Pharmaceuticals' current Earnings Yield (Joel Greenblatt) % of 17.54% is 16% below median its 10-year median of 20.81. Over the past 10 years, this metric has ranged from a low of 4.37 to a high of 41.86. The Drug Manufacturers industry median Earnings Yield (Joel Greenblatt) % is 3.17. Minapharm Pharmaceuticals' value of 17.54% is 453.3% above this industry median. Based on the distribution chart, Minapharm Pharmaceuticals ranks #218 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Minapharm Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Earnings Yield (Joel Greenblatt) % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Minapharm Pharmaceuticals ranks #218 out of 1008 companies for Earnings Yield (Joel Greenblatt) %. This places Minapharm Pharmaceuticals in the top 22% of its industry — outperforming the majority of peers. The industry median Earnings Yield (Joel Greenblatt) % is 3.17. Minapharm Pharmaceuticals' value of 17.54% is 453.3% above this benchmark. Historically, Minapharm Pharmaceuticals' own Earnings Yield (Joel Greenblatt) % has ranged from 4.37 to 41.86 over the past decade. While the company's 10-year median is 20.81 vs. the industry median of 3.17, Minapharm Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.17, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minapharm Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % of 17.54% is 453.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Minapharm Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minapharm Pharmaceuticals's current Earnings Yield (Joel Greenblatt) % is 17.54%, which is 16% below median its own 10-year median of 20.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£370.02, compared to a current price of E£766.83 — trading 107.2% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 17.54%, which is 16% below median its 10-year median of 20.81 and 453.3% above the Drug Manufacturers industry median of 3.17. Minapharm Pharmaceuticals' overall GF Score™ is 49/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Earnings Yield (Joel Greenblatt) % is 17.54% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued.
The current stock price of E£766.83 is trading 107.2% above its estimated GF Value™ of E£370.02.
GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for CAI:MIPH:
Earnings Yield (Joel Greenblatt) %: 17.54% (16% below median its 10-year median of 20.81)
GF Value™: E£370.02 vs. price of E£766.83 (107.2% above fair value)
Industry Position: 453.3% above the Drug Manufacturers median (#218 of 1008)
No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
49GF Score
Get the complete analysis for CAI:MIPH
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:MIPH has been successfully added to your 
